NEW YORK--(BUSINESS WIRE)--Enzo Therapeutics, Inc., a wholly owned subsidiary of Enzo Biochem, Inc. (NYSE:ENZ), has treated the first patient in a Phase I/II clinical trial of the company’s gene therapy for HIV-1 (Human Immunodeficiency Virus-Type 1) infection.
